In the study by Landi et al., self-reported urogenital symptoms data from 468 premenopausal and postmenopausal breast cancer patients, of whom 49% were receiving hormonal therapy either tamoxifen or aromatase inhibitors, were examined. The gene discussed is CYP19A1; the disease is breast carcinoma.